Skip to main content

Table 1 Patients’ clinical characteristics (n = 10) with diffuse cutaneous systemic sclerosis (SSc) before autologous hematopoietic stem cell transplantation (aHSCT) and graft characteristics at study inclusiona

From: Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients

  Group A patients (n = 5)   Group B patients (n = 5)   
  1 2 3 4 5 Mean (±SD) 1 2 3 4 5 Mean (±SD) Mean (±SD)
Patients characteristics at inclusion
 Age, years 40 56 53 47 24 44 ± 12.7 24 27 52 19 32 30.8 ± 12.7 37.4 ± 13.9
 Sex M M M F F M M F F F
 Disease duration, monthsb 6 18 29 20 18 18.2 ± 8.2 3 6 27 24 36 19.2 ± 14.1 18.7 ± 10.9
 Steroids at inclusion, mg/day 7 10 0 10 0 5.4 ± 5.1 0 7 0 0 0 1.7 ± 3.5 3.8 ± 4.6
 SHAQ (0–3) 0.87 2.87 1.625 2 1.8 ± 0.8 1.25 2 2.125 0.16 1.4 ± 0.9 1.6 ± 0.8
 mRSS (0–51) 26 22 37 29 25 27.8 ± 5.7 16 22 52 42 23 31 ± 15.2 29.4 ± 11.0
 FVC, % 56 89 87 108 58 79.6 ± 22.2 52 72 63 56 60.7 ± 8.8 71.2 ± 19.3
 DLCO, % predicted 45 75 72 56 48 59.2 ± 13.7 56 47 72 46 30 50.2 ± 15.4 54.7 ± 14.5
 LVEF, % 58 82 62 61 73 67.2 ± 10.0 60 63 67 70 65 ± 4.4 66.2 ± 7.7
 Serum creatinine, μmol/L 67 76 77 51 67.8 ± 12.0 52 73 60 59 71 63 ± 8.8 65.1 ± 10.0
 CRP level, mg/L 62 2 15 20 2 20.2 ± 24.7 9 51 66 13 10 35 ± 27.8 26.8 ± 25.6
 Anti-Scl-70 antibodies, U/ml 120 + 0 10.2 + 43.3 ± 66.5 0 + 39.1 130 21.3 47.6 ± 57.2 45.8 ± 55.8
Graft characteristics and engraftment duration
 CD34+ cells × 106 infused/kgc 4.9 2.9 4.9 2.5 5.3 4.1 ± 1.3 5.8 6.3 5.19 8.79 7.2 6.9 ± 2.0 5.5 ± 2.2
 CFU-GM cells × 104 infused/kgd 12.37 2.7 88 34.3 ± 46.7 23 48 9.97 52.56 91 44.9 ± 31.2 40.9 ± 34.7
 Days to 0.5 × 109 neutrophils/L 10 10 11 10 10 10.2 ± 0.4 10 7 10 9 9 9 ± 1.2 9.6 ± 1.1
 Days to 20 × 109 platelets/L 8 10 10 9 7 8.8 ± 1.3 8 7 10 12 6 8.6 ± 2.4 8.7 ± 1.8
 Days to 50 × 109 platelets/L 10 10 13 9 10 10.4 ± 1.5 9 7 Not reached 14 9 9.7 ± 3.0 10.1 ± 2.1
  1. Anti Scl-70 (antitopoisomerase I) antibodies were measured by ELISA and quantified results expressed in arbitrary units (U/ml)
  2. M male, F female, SHAQ Scleroderma Health Assessment Questionnaire, STE steroids, mRSS modified Rodnan skin thickness score, FVC forced vital capacity, DL CO diffusing capacity for carbon monoxide, LVEF left ventricular ejection fraction, MUGA multiple gated acquisition scan, CRP C-reactive protein. + positive for anti-Scl-70 antibodies
  3. aSee the “Results” section for description of groups
  4. bCalculated since first diagnosis of systemic sclerosis
  5. cQuantity of CD34+ progenitor cells contained in the graft. CD34+ cell recovery after cryopreservation was 95% (range 75–100%)
  6. dGM-CFUs/kg were counted on day 14 using a clonogenic progenitor assay as previously described[8]